ClinicalTrials.gg

Program

Simvastatin

Also written as “simvastatin”, “ezetimibe (+) simvastatin” and “Fenofibrate/Simvastatin”.

Its studies are mostly in Hypercholesterolemia · Diabetes Mellitus, Type 2 · Hyperlipidemias · Cardiovascular Diseases · Hypertension, led by 11 companies.

Furthest: phase 4, since Sep 7, 200565 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon290 open or runningphase 4since Sep 7, 2005Sep 21, 2004none ahead
Abbott80 open or runningphase 3since Mar 25, 2004Mar 25, 2004none ahead
Eli Lilly60 open or runningphase 2since Apr 15, 2010Apr 15, 2010none ahead
GlaxoSmithKline60 open or runningphase 3since Oct 28, 2005Oct 28, 2005none ahead
Merck60 open or runningphase 3since May 24, 2007May 24, 2007none ahead
Pfizer40 open or runningphase 4since Sep 8, 2005Sep 8, 2005none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Jul 21, 2010Jul 21, 2010none ahead
Biogen10 open or runningphase 4since Jun 25, 2007Jun 25, 2007none ahead
entero-therapeutics10 open or runningearly phase 1since Oct 3, 2016Oct 3, 2016none ahead
Medtronic10 open or runningearly phase 1since Jul 21, 2008Jul 21, 2008none ahead
Viatris10 open or runningphase 4since Aug 30, 2005Aug 30, 2005none ahead

Also a collaborator on its studies: immunogenics-llc, Regeneron Pharmaceuticals, celerion and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Aug 2, 2005.

  1. Jul 1, 2010Phase 1 study in Sleep Wake DisordersGlaxoSmithKline · NCT01299597 · 30 enrolled · Germany
  2. Jul 21, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01167933, NCT01167894
  3. Apr 13, 2011Phase 3 study in HypercholesterolemiaMerck · NCT01335997 · 1,139 enrolled
  4. Oct 29, 2011Phase 1 study in Diabetes Mellitus, Type 2Pfizer · NCT01469468 · 14 enrolled · United States
  5. Jun 26, 2012Phase 3 study in DyslipidemiasAbbott · NCT01674712 · 575 enrolled · Argentina, Czech Republic, Germany and more
  6. Aug 31, 2012Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT01678820 · 299 enrolled
  7. Sep 26, 2013Phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT01953835 · 37 enrolled · United States
  8. Oct 8, 2013Phase 1 study in Healthy VolunteersEli Lilly · NCT01960140 · 40 enrolled · United Kingdom
  9. May 28, 2014Phase 1 study in Healthy VolunteersEli Lilly · NCT02156492 · 62 enrolled · China
  10. Nov 20, 2014Phase 1 study in Healthy VolunteersEli Lilly · NCT02300259 · 48 enrolled · United States
  11. Mar 16, 2016Phase 1 study in DyslipidemiasEli Lilly · NCT02714569 · 60 enrolled · United States
  12. Oct 3, 2016entero-therapeutics's first study: early phase 1 study in Celiac DiseaseNew to entero-therapeuticsentero-therapeutics · NCT03011931 · 40 enrolled · United States
  13. Mar 6, 2019Phase 3 study in Hyperlipoproteinemia Type IIOrganon · NCT03884452 · 50 enrolled
  14. Dec 16, 2023Phase 1 study in ObesityEli Lilly · NCT06186622 · 50 enrolled · United States

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
AtorvastatinruleViatrisphase 4186
rosuvastatinruleAstraZenecaphase 4184
pitavastatinruleKowaphase 436

Studies

The newest 60 of 65 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06186622Obesity · United States1CompletedEli LillyJul 10, 202450
NCT03884452Hyperlipoproteinemia Type II3CompletedOrganonMay 24, 200150
NCT03011931Celiac Disease · United StatesEarly 1Completedentero-therapeuticsJan 201940
NCT02714569Dyslipidemias · United States1CompletedEli LillyFeb 15, 201760
NCT02300259Healthy Volunteers · United States1CompletedEli LillyApr 201548
NCT02156492Healthy Volunteers · China1CompletedEli LillyDec 201462
NCT01960140Healthy Volunteers · United Kingdom1CompletedEli LillyDec 201340
NCT01953835Lupus Erythematosus, Systemic · United States1CompletedGlaxoSmithKlineMar 10, 201437
NCT01678820Diabetes Mellitus, Type 23TerminatedMerckNov 1, 2013299
NCT01674712Dyslipidemias · Argentina, Czech Republic, Germany and more3CompletedAbbottOct 2013575
NCT01469468Diabetes Mellitus, Type 2 · United States1CompletedPfizerDec 201114
NCT01335997Hypercholesterolemia3TerminatedMerckJan 1, 20121,139
NCT01167933Healthy1CompletedDr. Reddy's LaboratoriesApr 200544
NCT01167894Healthy1CompletedDr. Reddy's LaboratoriesApr 200572
NCT01299597Sleep Wake Disorders · Germany1CompletedGlaxoSmithKlineFeb 26, 201030
NCT01138072Infections · United States1CompletedGlaxoSmithKlineAug 201014
NCT01105975Dyslipidemias · United States, Denmark, Germany and more2CompletedEli LillyJun 2011398
NCT01101568Diabetes Mellitus, Type 2 · United States1CompletedGlaxoSmithKlineJun 24, 201028
NCT00943124Dyslipidemias1CompletedMerckAug 2007220
NCT00935259Hypercholesterolemia1CompletedMerckOct 200931
NCT00862251Cardiovascular Diseases3CompletedOrganonMar 2011808
NCT00739050Lupus Erythematosus, Systemic4TerminatedOrganonFeb 1, 20084
NCT00720577Peripheral Arterial DiseaseEarly 1CompletedMedtronicJul 2007164
NCT00654628Hypercholesterolemia4CompletedOrganonJul 1, 2009173
NCT00653835Hypercholesterolemia4CompletedOrganonAug 1, 2004153
NCT00653523Hypercholesterolemia3CompletedOrganonJun 1, 2009151
NCT00652301Cholesterol3CompletedOrganonApr 200440
NCT00651560Hyperlipidemias3CompletedOrganonDec 23, 2005167
NCT00651391Hypercholesterolemia3TerminatedOrganonSep 1, 200428
NCT00650819Hypercholesterolemia3CompletedOrganonFeb 1, 2005240
NCT00650663Hypercholesterolemia4CompletedOrganonSep 1, 2004247
NCT00566267Hyperlipidemias3CompletedMerck58
NCT00551447Coronary Disease3CompletedOrganonMar 2003616
NCT00504439Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedGlaxoSmithKlineSep 6, 200736
NCT00496730Hypercholesterolemia3CompletedOrganonAug 2008256
NCT00492765Multiple Sclerosis · Denmark4CompletedBiogenApr 2010380
NCT00479713Hypercholesterolemia3CompletedOrganonMar 1, 2008618
NCT00479388Primary Hypercholesterolemia3CompletedMerckJul 20081,216
NCT00465088Hyperlipidemias · United States3CompletedAbbottFeb 2008199
NCT00462748Hypercholesterolemia3CompletedOrganonJun 2008786
NCT00442897Hypercholesterolemia4CompletedOrganonOct 2008229
NCT00423579Hypercholesterolemia4CompletedOrganonMar 1, 2008120
NCT00413972Hypercholesterolemia3CompletedOrganonNov 2006392
NCT00409773Hypercholesterolemia3CompletedOrganonJul 20081,143
NCT00398294Hypercholesterolemia · Taiwan4CompletedOrganonApr 4, 200630
NCT00389896HDL Cholesterol3CompletedOrganonOct 4, 2002150
NCT00362934Hyperlipidemias · Bulgaria, Czech Republic, Germany and more3CompletedAbbottAug 2008516
NCT00362206Hyperlipidemias · Greece, Israel, Romania and more3CompletedAbbottSep 2008423
NCT00352183Cardiovascular Diseases · Australia, Estonia, Hungary and more3CompletedAbbottAug 2008450
NCT00349375Hyperlipidemias · Czech Republic, Denmark, France and more3CompletedAbbottSep 20081,040
NCT00271817Hypercholesterolemia3CompletedOrganonFeb 20081,220
NCT00267280Hyperlipidemias · United States3TerminatedPfizerDec 2006640
NCT00267254Hyperlipidemias · United States3CompletedPfizer640
NCT00246701Hypertriglyceridemia3CompletedGlaxoSmithKlineJun 1, 2006256
NCT00166530Atherosclerosis4CompletedOrganonFeb 2007367
NCT00166504Hypercholesterolemia4CompletedOrganonOct 2007203
NCT00159835Cardiovascular Diseases · Denmark, Finland, Iceland and more4CompletedPfizer8,600
NCT00157924Hypercholesterolemia4CompletedOrganonSep 2007190
NCT00141141Hypercholesterolemia · Italy4CompletedViatris383
NCT00132717Hypercholesterolemia3CompletedOrganonJun 1, 2007450

How it is read

Names in the registry

  • “Simvastatin”, 44 entries
  • “simvastatin”, 14 entries
  • “ezetimibe (+) simvastatin”, 9 entries
  • “Fenofibrate/Simvastatin”, 5 entries
  • “Ezetimibe + Simvastatin”, 4 entries

Codes read as this program: MK0733.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.